Alexion Pharmaceuticals (NASDAQ:ALXN) Receives “Buy” Rating from William Blair

William Blair reaffirmed their buy rating on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a report issued on Friday morning, AnalystRatings.com reports.

A number of other brokerages have also recently commented on ALXN. BidaskClub raised shares of Alexion Pharmaceuticals from a sell rating to a hold rating in a research report on Monday, November 25th. Piper Jaffray Companies set a $180.00 target price on shares of Alexion Pharmaceuticals and gave the company a buy rating in a research report on Friday, September 6th. Morgan Stanley dropped their target price on shares of Alexion Pharmaceuticals from $177.00 to $170.00 and set an overweight rating on the stock in a research report on Friday, October 11th. Robert W. Baird set a $165.00 target price on shares of Alexion Pharmaceuticals and gave the stock a buy rating in a research note on Friday, August 30th. Finally, TheStreet cut shares of Alexion Pharmaceuticals from a b- rating to a c+ rating in a report on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have assigned a buy rating to the company. The stock has an average rating of Buy and an average target price of $156.37.

Shares of NASDAQ ALXN opened at $113.89 on Friday. The company has a market capitalization of $25.20 billion, a P/E ratio of 12.45, a price-to-earnings-growth ratio of 0.87 and a beta of 1.67. Alexion Pharmaceuticals has a 52-week low of $92.56 and a 52-week high of $141.86. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.45 and a current ratio of 3.98. The company’s 50 day moving average price is $108.47 and its 200-day moving average price is $112.81.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Wednesday, October 23rd. The biopharmaceutical company reported $2.79 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.47 by $0.32. Alexion Pharmaceuticals had a net margin of 31.05% and a return on equity of 21.21%. The company had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.24 billion. During the same period in the prior year, the company posted $2.02 earnings per share. Alexion Pharmaceuticals’s revenue for the quarter was up 23.0% compared to the same quarter last year. Analysts forecast that Alexion Pharmaceuticals will post 9.43 earnings per share for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Resources Management Corp CT ADV bought a new stake in Alexion Pharmaceuticals during the 3rd quarter worth approximately $244,000. Beck Bode LLC boosted its position in shares of Alexion Pharmaceuticals by 7.0% during the third quarter. Beck Bode LLC now owns 25,516 shares of the biopharmaceutical company’s stock valued at $2,499,000 after buying an additional 1,678 shares during the last quarter. Man Group plc grew its holdings in Alexion Pharmaceuticals by 347.3% during the third quarter. Man Group plc now owns 513,104 shares of the biopharmaceutical company’s stock worth $50,254,000 after buying an additional 398,394 shares in the last quarter. Partner Investment Management L.P. bought a new stake in Alexion Pharmaceuticals during the third quarter worth $2,168,000. Finally, Redmile Group LLC bought a new stake in Alexion Pharmaceuticals during the third quarter worth $113,826,000. 91.62% of the stock is owned by institutional investors and hedge funds.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

See Also: Google Finance Portfolio Tips and Tricks

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.